Clinical and Translational Research
Copyright ©The Author(s) 2024.
World J Gastrointest Oncol. May 15, 2024; 16(5): 1908-1924
Published online May 15, 2024. doi: 10.4251/wjgo.v16.i5.1908
Figure 6
Figure 6 Drug sensitivity analysis. Drug sensitivity analysis showed that patients with a high-risk signature were resistant or sensitive to chemotherapy and targeted therapy with different treatments. A: AZD7762; B: Dabrafenib; C: Erlotinib; D: Luminespib; E: OF-1; F: OSI-027.